A warm welcome to Dr James Jett

December 1, 2015

Oncimmune is delighted to have Dr James Jett join the team as Chief Medical Officer from the 1st January 2016

Dr Jett will be based in the US and will support all aspects of research and development as Oncimmune continues the further commercialisation of EarlyCDT®-Lung on a global basis and the launch of new EarlyCDT® cancer tests.

Dr Jett is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the USA, where his research includes conducting clinical trials related to the screening and early detection of lung cancer. Prior to joining National Jewish Health in 2010, he held appointments as Professor of Medicine at Mayo Medical School and the University of Pittsburgh.

He has been the principal investigator on the National Jewish Health study on EarlyCDT-Lung, interim results of which were presented at World Lung Cancer conference in September 2015. He has also published and presented results of an audit of Oncimmune’s first 1600 commercial tests.

Commenting on his appointment, Dr James Jett said: “I have followed Oncimmune’s science and the development of the EarlyCDT-Lung test for many years. Oncimmune has pioneered autoantibody testing for cancer and EarlyCDT-Lung can play an important part in the early detection of lung cancer and the significant improvement in patient prognosis that early detection brings. Current data suggests it will also have a role to play in risk assessment of CT nodules. I look forward to working with the team as they continue to build on the technology’s potential.”

Geoffrey Hamilton-Fairley, CEO of Oncimmune commented: “As a world-recognised lung cancer specialist, James’ experience and insight could not be more relevant to the work we are doing at Oncimmune around the continued development and commercialisation of EarlyCDT-Lung. His clinical expertise and experience in overviewing and designing trials will be of great value to the company as we expand into other cancers. James is well acquainted with our science and validation data and it is an honour to welcome him to Oncimmune.”

Dr Jett’s research interests focus on the screening and early detection of lung cancer. His research has been funded by the National Institutes of Health and the National Cancer Institute and he was part of a research team that discovered how CT screening can be an effective tool to detect lung cancer early in high-risk patients.

Dr Jett is board certified in internal medicine and pulmonary medicine, and he completed his medical degree at the University of Missouri, Columbia. He completed a residency in internal medicine and a fellowship in thoracic diseases at Mayo Graduate School of Medicine, and a research fellowship at the National Cancer Institute, National Institutes of Health. He is on the Scientific Advisory Committee for the American Lung Association and was an External Review Chair for the Terry Fox Research Institute, Lung Cancer Grant.

Dr Jett has served in journal review and editorial activities for many medical publications, including the American Journal of Respiratory and Critical Care Medicine, American Journal of the Medical Sciences, Cancer, Chest, International Journal of Cancer, Lung Cancer and The New England Journal of Medicine. Dr. Jett was editor-in-chief of the Journal of Thoracic Oncology from 2006 to 2012 and he is currently the Co-Editor of the Lung Cancer Section of the electronic textbook “Up-To-Date”.


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept